PharmaEssentia (6446) Q1 2026 earnings summary

Executive summary

• Achieved strong revenue growth and profitability for Q1 2026, with significant increases in operating revenue and net income year-over-year.

• Continued expansion of global operations, including new subsidiaries and acquisitions in Puerto Rico, Canada, and Taiwan.

• Ongoing investment in R&D and clinical trials, with multiple international agreements and licensing deals.

Financial highlights

• Operating revenue for Q1 2026 was NTD 5,121,378 thousand, up 57% year-over-year.

• Net income for Q1 2026 reached NTD 2,149,627 thousand, a 70% increase from Q1 2025.

• Gross margin improved to 88% from 89% year-over-year, with operating income margin rising to 41%.

• Basic EPS for Q1 2026 was NTD 5.79, up from NTD 3.42 in Q1 2025.

• Cash and cash equivalents increased to NTD 24,175,410 thousand as of March 31, 2026.

Outlook and guidance

• Board approved further investments in subsidiaries and acquisitions to support global expansion.

• Continued focus on R&D, clinical trials, and new product launches to drive future growth.